SCHEMBL24378575

SCHEMBL24378575

Bc1cn2c(N3CCOCC3)cc(Cl)nc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 4/20 0.44
MAPT P10636 5/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
KMT2A Q03164 3/20 0.40
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
POLB P06746 1/20 0.34
RAF1 P04049 1/20 0.33
BRAF P15056 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
AR P10275 1/20 0.33
CRHR1 P34998 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HPGD P15428 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27009156 0.83 KDM4E (0.56) KDM4EALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL24378544 0.80 KDM4E (0.42) KDM4EALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL24378542 0.74 CYP1A2 (0.42) KDM4EALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL24378546 0.72 DPP4 (0.45) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL24378616 0.71 CYP1A2 (0.42) KDM4EALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL27009150 0.69 CYP1A2 (0.42) KDM4EALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL24378615 0.69 CYP1A2 (0.40) KDM4EALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL13263839 0.68 PDE10A (0.54) KDM4EALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL22727799 0.68 POLB (0.43) KDM4EALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL17884206 0.66 KMT2A (0.46) ALDH1A1MAPTCYP1A2CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
WO-2022086993-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 KDM4E 1460/4885ALDH1A1 4878/4885MAPT 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.